跳至主要内容
临床试验/ACTRN12622001141730
ACTRN12622001141730尚未招募未知

A Multi-centre, Prospective, Clinical Outcomes Study to evaluate the MPRES Femoral Stem survivorship (efficacy) following primary Total Hip Arthroplasty

Medacta Australia Pty Ltd0 个研究点目标入组 280 人开始时间: 2022年8月19日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Male & Females 18-75 years old
  • Use of the non TGA approved (pre-market) Medacta MPRES femoral stem prosthesis.
  • Ability to give informed consent.
  • Qualify for primary total hip arthroplasty surgery with cementless fixation
  • Primary diagnosis of non-Inflammatory Degenerative Joint Disease
  • Skeletally mature
  • Good bone density
  • BMI less than or equal to 40.

排除标准

  • Previous hip replacement or fusion on affected side
  • Active infection in the affected joint
  • Intra-articular fracture
  • Neuromuscular or neurosensory deficiency
  • Diagnosed metabolic disorder which may impair bone formation or bone quality
  • Immunologically suppressed

研究者

相似试验